Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Bausch Health Companies Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, TODAY ANNOUNCED THE EUROPEAN LAUNCH OF THE BI-BLADE+ ADVANCED DUAL-PORT VITRECTOMY CUTTER ON THE STELLARIS ELITE VISION ENHANCEMENT SYSTEM. THE LAUNCH OF BI-BLADE+ IS THE LATEST EXAMPLE OF OUR COMMITMENT TO DELIVERING MEANINGFUL INNOVATION IN EUROPE, SAID LUC BONNEFOY, PRESIDENT, SURGICAL, BAUSCH + LOMB. STELLARIS ELITE HAS.

BAUSCH + LOMB LAUNCHES BI-BLADE+ DUAL-PORT VITRECTOMY CUTTER IN EUROPE

FIRST QUARTER CONSOLIDATED REVENUES OF $2.52 BILLION, UP 12% ON A REPORTED BASIS AND 7% ON AN ORGANIC (NON-GAAP)1 BASIS OVER THE PRIOR YEAR PERIOD GAAP NET LOSS ATTRIBUTABLE TO BAUSCH HEALTH OF $1,423 MILLION AND GAAP NET LOSS OF $1,431 MILLION, INCLUSIVE OF A $1,426 MILLION GOODWILL IMPAIRMENT CHARGE GAAP LOSS PER SHARE OF ($3.82) (BASIC AND DILUTED) COMPARED TO ($0.16) IN THE PRIOR YEAR PERIOD ADJUSTED EARNINGS PER DILUTED SHARE (NON-GAAP) OF $0.78 COMPARED TO $0.59 IN THE PRIOR YEAR PERIOD, AN INCREASE OF 32% CONSOLIDATED ADJUSTED EBITDA ATTRIBUTABLE TO BAUSCH HEALTH (NON-GAAP)1 OF $837 MILLION, UP 27% ON A REPORTED BASIS OVER THE PRIOR YEAR PERIOD BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST QUARTER 2026 RESULTS DELIVERED TWELFTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR REVENUE GROWTH AND ADJUSTED EBITDA (NON-GAAP)1 GROWTH, WITH 14% REPORTED AND 9% ORGANIC (NON-GAAP)1 REVENUE GROWTH AND 17% ADJUSTED EBITDA (NON-GAAP)1 GROWTH GENERATED $319 MILLION IN ADJUSTED CASH FLOW FROM OPERATIONS (NON-GAAP) 1 REAFFIRMING FULL-YEAR 2026 REVENUE, ADJUSTED EBITDA (NON-GAAP)1, AND ADJUSTED CASH FLOW FROM OPERATIONS (NON-GAAP)1 GUIDANCE LAVAL, QC, APRIL 29, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) ("BAUSCH HEALTH" OR THE "COMPANY" OR "WE" OR "OUR") TODAY ANNOUNCED ITS FIRST QUARTER 2026 FINANCIAL RESULTS AND OTHER KEY UPDATES FROM THE QUARTER. "OUR FIRST QUARTER PERFORMANCE MARKS TWELVE CONSECUTIVE PERIODS OF YEAROVERYEAR GROWTH IN REVENUE, ADJUSTED EBITDA FOR BAUSCH HEALTH EXCLUDING BAUSCH + LOMB, REFLECTING STRATEGIC EXECUTION AND DISCIPLINED ACCOUNTABILITY ACROSS OUR ORGANIZATION.

BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, TODAY ANNOUNCED THAT OPHTHALMOLOGY AND THERAPY PUBLISHED A NARRATIVE REVIEW HIGHLIGHTING THE ROLE OF CERTAIN B VITAMINS IN REDUCING THE RISK OF DEVELOPMENT AND PROGRESSION OF AMD1, A LEADING CAUSE OF VISION LOSS IN AMERICANS 50 YEARS OF AGE OR OLDER.2 DRAWING ON MORE THAN TWO DECADES OF SCIENTIFIC RESEARCH, THE PUBLICATION SYNT.

BAUSCH + LOMB ANNOUNCES PUBLISHED REVIEW EXAMINING THE ROLE OF B VITAMINS IN REDUCING RISK AND PROGRESSION OF AGE-RELATED MACULAR DEGENERATION

THE SKIN RECOVERY EMULSION FOR DRY, SENSITIVE, OR STRESSED SKIN IS NOW AVAILABLE THROUGH SELECT ONLINE CHANNELS LAVAL, QC, APRIL 14, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) AND ITS DERMATOLOGY BUSINESS, ORTHO DERMATOLOGICS, TODAY ANNOUNCED BIAFINE SKIN RECOVERY EMULSION IS NOW OFFERED THROUGH CONVENIENT ONLINE ORDERING IN THE UNITED STATES. THE WELL-KNOWN FRENCH SKINCARE FORMULA IS AVAILABLE THROUGH SELECT ONLINE CHANNELS.

BAUSCH HEALTH'S DERMATOLOGY BUSINESS, ORTHO DERMATOLOGICS, ANNOUNCES THE LAUNCH OF BIAFINE, AN ICONIC FRENCH SKINCARE PRODUCT, THROUGH CONVENIENT ONLINE ORDERING

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION HAS GRANTED 510(K) CLEARANCE FOR THE BI-BLADE+ ADVANCED DUAL-PORT VITRECTOMY CUTTER AND THE ADAPTIVE FLUIDICS ADVANCED UPDATE ON THE STELLARIS ELITE VISION ENHANCEMENT SYSTEM. RETINAL SURGEONS WHO ARE FAMILIAR WITH OUR BI-BLADE TECHNOLOGY UNDERSTAND THE BENEFITS OF IT.

BAUSCH + LOMB RECEIVES FDA 510(K) CLEARANCE FOR BI-BLADE+ DUAL-PORT VITRECTOMY CUTTER AND ADAPTIVE FLUIDICS ADVANCED UPDATE

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, TODAY ANNOUNCED EUROPEAN COMMERCIAL AVAILABILITY OF THE PRELOADED ENVISTA ENVY FULL RANGE OF VISION INTRAOCULAR LENS (IOL), WHICH OFFERS EXCELLENT DYSPHOTOPSIA TOLERANCE ON THE WIDELY USED ENVISTA IOL PLATFORM. BAUSCH + LOMB NOW OFFERS TWO FULL RANGE OF VISION PREMIUM IOLS - ENVISTA ENVY AND LUXLIFE TO MEET THE EVOLVING NEEDS.

BAUSCH + LOMB LAUNCHES PRELOADED ENVISTA ENVY FULL RANGE OF VISION INTRAOCULAR LENSES IN EUROPE

LAVAL, QC, MARCH 31, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) WILL RELEASE FIRST QUARTER 2026 FINANCIAL RESULTS AFTER MARKET CLOSE ON WEDNESDAY, APRIL 29, 2026. BAUSCH HEALTH WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 5:00 P.M.

BAUSCH HEALTH TO ANNOUNCE FIRST QUARTER 2026 RESULTS ON APRIL 29, 2026

BAUSCH HEALTH IS OFFERING SCHOLARSHIPS TO SIX STUDENTS IMPACTED BY DERMATOLOGIC CONDITIONS, WITH APPLICATIONS OPEN THROUGH JUNE 2026 LAVAL, QC, MARCH 26, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) AND ITS DERMATOLOGY BUSINESS, ORTHO DERMATOLOGICS, TODAY ANNOUNCED THE 2026 ASPIRE HIGHER SCHOLARSHIP PROGRAM, WITH APPLICATIONS OPEN THROUGH JUNE 10, 2026. THE PROGRAM WILL AWARD SIX EXCEPTIONAL STUDENTS, IMPACTED BY DERMATOLOGIC CONDITIONS WITH SCHOLARSHIPS OF UP TO $10,000 EACH TO SUPPORT THEIR PURSUIT OF HIGHER EDUCATION.

BAUSCH HEALTH ANNOUNCES ORTHO DERMATOLOGICS 2026 ASPIRE HIGHER SCHOLARSHIP PROGRAM

LOS ANGELES, MARCH 13, 2026 (GLOBE NEWSWIRE) -- THE PORTNOY LAW FIRM ADVISES BAUSCH + LOMB CORPORATION , ( BLCO " OR THE "COMPANY") ( NYSE : BLCO ) INVESTORS THAT THE FIRM HAS INITIATED AN INVESTIGATION INTO POSSIBLE SECURITIES FRAUD, AND MAY FILE A CLASS ACTION ON BEHALF OF INVESTORS.

BAUSCH + LOMB CORPORATION INVESTIGATED BY THE PORTNOY LAW FIRM

LAVAL, QC, FEB. 23, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, AND SOLTA MEDICAL, A GLOBAL LEADER IN MEDICAL AESTHETICS, TODAY ANNOUNCED THE LAUNCH OF THE CLEAR + BRILLIANTTOUCH LASER IN CANADA. THE DEVICE WAS APPROVED BY HEALTH CANADA ON MAY 20, 2025, MARKING AN IMPORTANT MILESTONE AS DEMAND FOR NONINVASIVE SKIN REJUVENATION TREATMENTS CONTINUES TO GROW ACROSS CANADA.

Bausch Health Companies Inc.

BHC

Price

Financial Reports

No items found.

Press Releases

Bausch Health Companies Inc.

BHC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BHC